Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy.

Ambs S, Marincola FM, Thurin M.

Cancer Res. 2008 Jun 1;68(11):4031-3. doi: 10.1158/0008-5472.CAN-08-0521. No abstract available.

2.

Thoracoscopic versus thoracotomy approaches to lobectomy: differential impairment of cellular immunity.

Whitson BA, D'Cunha J, Andrade RS, Kelly RF, Groth SS, Wu B, Miller JS, Kratzke RA, Maddaus MA.

Ann Thorac Surg. 2008 Dec;86(6):1735-44. doi: 10.1016/j.athoracsur.2008.07.001.

PMID:
19021967
3.

[PCR-technology in the diagnosis, prognosis and therapy of oncologic disease].

Vinogradskaia GR, Marinets OV.

Vopr Onkol. 2001;47(1):7-17. Review. Russian. No abstract available.

PMID:
11317541
4.

Identification of immunologic biomarkers associated with clinical response after immune-based therapy for cancer.

Dang Y, Disis ML.

Ann N Y Acad Sci. 2009 Sep;1174:81-7. doi: 10.1111/j.1749-6632.2009.04937.x.

PMID:
19769740
5.

Summary of the primer on tumor immunology and the biological therapy of cancer.

Li Y, Liu S, Margolin K, Hwu P.

J Transl Med. 2009 Jan 28;7:11. doi: 10.1186/1479-5876-7-11.

6.

Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.

Yamashita S, Chujo M, Tokuishi K, Anami K, Miyawaki M, Yamamoto S, Kawahara K.

J Thorac Cardiovasc Surg. 2009 Dec;138(6):1303-8. doi: 10.1016/j.jtcvs.2009.08.003. Epub 2009 Oct 9.

7.

Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR.

Koga T, Tokunaga E, Sumiyoshi Y, Oki E, Oda S, Takahashi I, Kakeji Y, Baba H, Maehara Y.

Hepatogastroenterology. 2008 May-Jun;55(84):1131-5.

PMID:
18705345
8.

Personalized cancer diagnostics and therapeutics.

Roukos DH.

Expert Rev Mol Diagn. 2009 Apr;9(3):227-9. doi: 10.1586/erm.09.6. No abstract available.

PMID:
19379081
9.

Regulatory T-cells are possible effect prediction markers of immunotherapy for cancer patients.

Wada J, Yamasaki A, Nagai S, Yanai K, Fuchino K, Kameda C, Tanaka H, Koga K, Nakashima H, Nakamura M, Tanaka M, Katano M, Morisaki T.

Anticancer Res. 2008 Jul-Aug;28(4C):2401-8.

10.

Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.

Nowecki ZI, Rutkowski P, Kulik J, Siedlecki JA, Ruka W.

Br J Dermatol. 2008 Sep;159(3):597-605. doi: 10.1111/j.1365-2133.2008.08710.x. Epub 2008 Jul 4.

PMID:
18616789
11.

Show me the genes - I will tell you who/how to treat!

Cardoso F.

Breast Cancer Res. 2005;7(2):77-9. Epub 2005 Feb 14. No abstract available.

12.

[Some aspects of patients' immune response at different degree of intensity of vibration disease].

Abramatets EA, Lakhman OL, Kudaeva IV.

Med Tr Prom Ekol. 2007;(11):30-3. Russian.

PMID:
18274126
13.

New molecular assays for cancer diagnosis and targeted therapy.

Lea P, Ling M.

Curr Opin Mol Ther. 2008 Jun;10(3):251-9. Review.

PMID:
18535932
14.

Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins.

Dodds MG, Frederiksen KS, Skak K, Hansen LT, Lundsgaard D, Thompson JA, Hughes SD.

Cancer Immunol Immunother. 2009 Jun;58(6):843-54. doi: 10.1007/s00262-008-0600-8. Epub 2008 Oct 17.

PMID:
18925392
15.

Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.

Yoshihara K, Tajima A, Komata D, Yamamoto T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Fujiwara H, Kudo Y, Inoue I, Tanaka K.

Cancer Sci. 2009 Aug;100(8):1421-8. doi: 10.1111/j.1349-7006.2009.01204.x. Epub 2009 May 26.

16.

Does the presence of circulating tumor cells in the venous drainage of curative colorectal cancer resections determine prognosis? A meta-analysis.

Katsuno H, Zacharakis E, Aziz O, Rao C, Deeba S, Paraskeva P, Ziprin P, Athanasiou T, Darzi A.

Ann Surg Oncol. 2008 Nov;15(11):3083-91. doi: 10.1245/s10434-008-0131-8. Epub 2008 Sep 12.

PMID:
18787906
17.

Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY.

Cell Res. 2008 Oct;18(10):997-1006. doi: 10.1038/cr.2008.282.

PMID:
18766170
18.

Cancer vaccine enhanced, non-tumor-reactive CD8(+) T cells exhibit a distinct molecular program associated with "division arrest anergy".

Beyer M, Karbach J, Mallmann MR, Zander T, Eggle D, Classen S, Debey-Pascher S, Famulok M, J├Ąger E, Schultze JL.

Cancer Res. 2009 May 15;69(10):4346-54. doi: 10.1158/0008-5472.CAN-08-3796. Epub 2009 May 12.

19.

Use of DNA methylation for cancer detection: promises and challenges.

Zhu J, Yao X.

Int J Biochem Cell Biol. 2009 Jan;41(1):147-54. doi: 10.1016/j.biocel.2008.09.003. Epub 2008 Sep 13. Review.

PMID:
18834953
20.

Opening the gateway to tumors.

Kershaw MH.

Nat Med. 2008 Jan;14(1):13-4. doi: 10.1038/nm0108-13. No abstract available.

PMID:
18180710

Supplemental Content

Support Center